Capricor Therapeutics CAPR Business Segments — Research And Development Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Capricor Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Capricor Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Capricor Therapeutics's business segments — research and development expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Capricor Therapeutics's business segments — research and development expense?
- Capricor Therapeutics (CAPR) reported business segments — research and development expense of $27.38M in Q1 2026.
- How has Capricor Therapeutics's business segments — research and development expense changed year-over-year?
- Capricor Therapeutics's business segments — research and development expense increased by 44.7% year-over-year, from $18.92M to $27.38M.
- What does business segments — research and development expense mean?
- This metric represents the total aggregate costs incurred by the business segment to conduct research, clinical trials, and product development. It is the primary measure of investment in the company's future revenue-generating potential through its pipeline of biological therapies. High levels of this expense are typical for biotechnology firms in the development stage.